Compare Dover Corp (DOV) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dover Corp vs TG Therapeutics Inc — how do they compare? Dover Corp trades at $188.84 (market cap $25.45B), while TG Therapeutics Inc trades at $55.11 (market cap $8.16B). The key difference: Dover Corp is far larger — about 3.1× TG Therapeutics Inc's market cap, and Dover Corp pays a 1.11% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dover Corp for 73 Days and TG Therapeutics Inc for 16 Days on average.
| DOV | TGTX | |
|---|---|---|
Market Cap | $25.45B | $8.16B |
Volume | 661,758 | 1,735,121 |
Sector | Industrials | Health |
52-Week High | $233.31 | $59.06 |
52-Week Low | $161.16 | $26.94 |
Typical Hold Time | 73 Days | 16 Days |
Enterprise Value | $26.95B | $8.37B |
Dividend Yield | 1.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOV trades at $189.32, up 0.55% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported consistent earnings beats in recent quarters, with Q3 2026 results pending. Revenue for 2025 was $8.09B, with a net income margin of 13.48%, while analyst consensus is strongly positive with a $243.20 price target. Recent news highlights product launches and strategic acquisitions, such as the completion of the Cloeren acquisition in August 2026.
DOV presents a favorable fundamental outlook with solid profitability and analyst support, though technical indicators suggest near-term caution. Upside potential exists from earnings momentum and dividend reliability, but risks include market volatility and execution challenges from recent acquisitions. The stock's current price is below the consensus target, indicating room for growth if quarterly results meet expectations.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dover Corp
Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
